research use only

Auranofin (SKF-39162) TrxR Inhibitor

Name: Auranofin (SKF-39162)
Brand: Selleck Chemicals
SKU: S4307
Availability: InStock
Rating: 5 (6 reviews)

Cat.No.S4307

Auranofin is an inhibitor of thioredoxin reductase (TrxR) with IC50 of 88 nM for purified H. pylori TrxR in cell-free assay. Auranofin has anti-cancer activity and can completely inhibit bacterial growth at 1.2 μM. Auranofin is an FDA-approved gold-containing compound used for the treatment of rheumatoid arthritis.

Chemical Structure

Molecular Weight: 678.48

Jump to

Quality Control

Batch: Purity: 100.00%

100.00

Related Targets	Dehydrogenase HSP Transferase P450 (e.g. CYP17) PDE phosphatase PPAR Vitamin Carbohydrate Metabolism Mitochondrial Metabolism
Other Thioredoxin Reductase Products	TRi-1 TXNRD1 Antibody [D10G24] TRXR1 Antibody [M16L20]

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (147.38 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 100 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	678.48	Formula	C₂₀H₃₄AuO₉PS	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	34031-32-8	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	SKF39162			Smiles	CCP(CC)CC.CC(=O)OCC1C(C(C(C(O1)[S-])OC(=O)C)OC(=O)C)OC(=O)C.[Au+]

Mechanism of Action

Targets/IC₅₀/Ki	TrxR (Cell-free assay) 88 nM
In vitro	Auranofin (Ridaura, SKF-39162) is an inhibitor of thioredoxin reductase (TrxR) with IC50 of 88 nM for purified H. pylori TrxR in cell-free assay.
In vivo	This compound is a small molecule inhibitor of NONO that suppressed GBM tumor growth in an orthotopic xenograft model in mice.
References	[1] https://pubmed.ncbi.nlm.nih.gov/27279627/ [2] https://pubmed.ncbi.nlm.nih.gov/35910786/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02089048	Completed	Amoebiasis	National Institute of Allergy and Infectious Diseases (NIAID)	April 2 2014	Phase 1
NCT01747798	Completed	Recurrent Fallopian Tube Cancer\|Recurrent Ovarian Epithelial Cancer\|Recurrent Primary Peritoneal Cavity Cancer	Mayo Clinic	November 2 2012	Early Phase 1
NCT01419691	Completed	Chronic Lymphocytic Leukemia (CLL)\|Small Lymphocytic Lymphoma\|Leukemia Prolymphocytic	University of Kansas Medical Center\|The Leukemia and Lymphoma Society\|Kansas Bioscience Authority\|Therapeutics for Rare and Neglected Diseases (TRND)	September 2011	Phase 2
NCT02176135	Withdrawn	HIV	Vaccine and Gene Therapy Institute Florida\|University of Miami		Phase 1\|Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):